Tanwar, S and Wright, M and Foster, GR and Ryder, SD and Mills, PR and Cramp, ME and Parkes, J and Rosenberg, WM (2012) Randomized clinical trial: a pilot study investigating the safety and effectiveness of an escalating dose of peginterferon α-2a monotherapy for 48 weeks compared with standard clinical care in patients with hepatitis C cirrhosis. Eur J Gastroenterol Hepatol , 24 (5) 543 - 550. 10.1097/MEG.0b013e3283513e69.
Full text not available from this repository.
Abstract
A substantial proportion of patients with chronic hepatitis C virus (HCV) cirrhosis fail to eradicate infection and develop liver-related complications. Despite evidence that interferon-α has an antifibrotic effect, clinical trials have demonstrated that low-dose maintenance interferon does not improve outcomes in patients with compensated HCV cirrhosis following a lead-in phase of interferon. In a pilot study, we have investigated the efficacy of an escalating dose of pegylated interferon α-2a (PEG-IFN2a) as compared with standard clinical care in patients with more advanced HCV Child's A or B cirrhosis without a lead-in phase.
| Type: | Article |
|---|---|
| Title: | Randomized clinical trial: a pilot study investigating the safety and effectiveness of an escalating dose of peginterferon α-2a monotherapy for 48 weeks compared with standard clinical care in patients with hepatitis C cirrhosis. |
| Location: | England |
| DOI: | 10.1097/MEG.0b013e3283513e69 |
| Language: | English |
| Keywords: | Adult, Antiviral Agents, Biological Markers, Dose-Response Relationship, Drug, Female, Hepatitis C, Chronic, Humans, Interferon-alpha, Kaplan-Meier Estimate, Liver Cirrhosis, Male, Middle Aged, Pilot Projects, Polyethylene Glycols, Prospective Studies, Quality of Life, Recombinant Proteins, Treatment Outcome |
Archive Staff Only: edit this record